Loading
A phase 2/3 trial testing Ivospemin in pancreatic ductal adenocarcinoma, now recruiting.
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer is a phase 2/3 interventional study registered as NCT05254171, led by Panbela Therapeutics, and recruiting on the registry. Official title: A Randomised, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma. Planned enrolment is 600 participants (estimated). The study started in 2022-08-08 and primary completion is expected in 2026-08-29. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/